By Fineline Cube 
China-based Bio-Thera Solutions Inc. (SHA: 688177) has announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its BAT7111, a bispecific antibody (BsAb) targeting PD-1 and 4-1BB (CD137). This approval allows the company to proceed with clinical trials for the treatment of advanced solid tumors.
BAT7111: Mechanism and Innovation
BAT7111 is an in-house developed bispecific antibody designed to target PD-1 and 4-1BB, a molecule primarily expressed on activated CD8+ effector T cells. By engaging 4-1BB, a T-cell co-stimulatory molecule, BAT7111 enhances immune responses by maintaining immune homeostasis, reducing immune cell apoptosis, and improving immune memory. This dual-targeting approach aims to amplify the anti-tumor effects of immunotherapy.
Clinical Development and Future Outlook
With clinical approval secured, Bio-Thera Solutions is poised to initiate trials to evaluate the safety and efficacy of BAT7111 in patients with advanced solid tumors. This marks a significant step forward in the development of innovative immunotherapies targeting the complex tumor microenvironment.-Fineline Info & Tech